AbCellera Biologics
Income Statement
Last updated:
Income statement is a financial statement that shows how profitable a business was over a given reporting period presenting its revenue, expenses or net income. AbCellera Biologics's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 92% to $38,025,000. The net income dropped to -$146,398,000 and profit margin reached -385%. Total operating expenses were $275,232,000.
Profit Margin
| 2018 | 8.83M | 309K | 3.5% |
|---|---|---|---|
| 2019 | 11.61M | -2.41M | -20.84% |
| 2020 | 233.15M | 118.91M | 51% |
| 2021 | 375.20M | 153.46M | 40.9% |
| 2022 | 485.42M | 158.51M | 32.66% |
| 2023 | 38.02M | -146.39M | -385% |
ABCL Income Statement (2018 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|
Revenue | ||||||
Revenue | 38.02M | 485.42M | 375.20M | 233.15M | 11.61M | 8.83M |
Cost of revenue | 0 | 66.43M | 45.51M | 27.14M | 10.11M | 0 |
Gross profit | 38.02M | 418.98M | 329.68M | 206.01M | 1.49M | 8.83M |
Operating exp. | ||||||
Research and development | 175.65M | 107.87M | 62.06M | 29.39M | 10.11M | 5.80M |
Selling and marketing | 14.18M | 11.27M | 6.91M | 3.84M | 1.26M | 712K |
Total operating expenses | 275.23M | 191.92M | 107.78M | 41.66M | 13.95M | 7.99M |
Operating income | -237.20M | 216.51M | 204.41M | 156.03M | -4.11M | -753K |
Other income (expenses), net | 63.17M | 22.58M | 14.73M | 1.80M | 1.90M | -362K |
Income before tax | -174.02M | 239.09M | 219.14M | 157.83M | -2.21M | 309K |
Income tax expense | -27.63M | 80.58M | 65.68M | 38.91M | 209.19K | 1.27M |
Net income | -146.39M | 158.51M | 153.46M | 118.91M | -2.41M | 309K |
Earnings per share | ||||||
Basic EPS | -0.51 | 0.56 | 0.56 | 0.44 | -0.01 | 0.00 |
Diluted EPS | -0.51 | 0.5 | 0.48 | 0.44 | -0.01 | 0.00 |
| Data source | Data source | Data source | Data source |